Date Hour Room Track
28th November,2017 9:30 - 11:00 am Salon Madrid 4 Track 3
  • What are the consequences of the increasing interactions and partnerships between pharma and VCs at the initial stages of pre-seed, seed and Series A?
  • Are we talking Entente Cordiale or open rivalry?
  • What is the part to play for Corporate VC in that context?
Michael Nowak - Nowak Ventures
Lucas de Breed - Inkef Capital
Detlev Mennerich - Boehringer Ingelheim Ventures
Pierre Belichard - Enterome Bioscience
Nathalie ter Wengel - Pfizer

Continue your tour